<DOC>
	<DOC>NCT02444637</DOC>
	<brief_summary>Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA &amp; HSA, is authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type. In this trial, the investigators will be studying the effectiveness of Rivastigmine in subjects with AD and cerebrovascular disease.</brief_summary>
	<brief_title>Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Age between 5085 years Diagnosis of dementia of the Alzheimer's type according to the National Institute of AgeingAlzheimer's Association Criteriah MRI brain (with T2 or FLAIR sequences) performed within a 12 month period from time of recruitment demonstrating the presence of WMH of â‰¥2 on the Fazekas scale (Score range of 03 wherein a score of 1 indicates mild WMH, 2 indicates moderate WMH and 3 indicates severe WMH).i Clinical Dementia Rating score of 12j MiniMental State Examination (MMSE) scores of 1226 inclusivek English or Mandarin speaking, literate participants Severe neurological, psychiatric or systemic disease which in the opinion of the clinician could interfere with trial assessments The use of any investigational drugs, new psychotropic or dopaminergic agents, cholinesterase inhibitors or anticholinergic agents during the 4 weeks prior to recruitment Known skin allergy or previous allergic reaction to Rivastigmine patch</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>